Shortwave Intervention for Diabetic Peripheral Neuropathy.
A legfontosabb adatok
- Ki végzi
- Chongqing Medical University
- Hol
- Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 202 fő, tervezett
- Kezdés
- 2026. máj. 20.
- Várható befejezés
- 2027. máj. 20.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport színlelt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Short-Wave Diathermy
- Placebo treatment group
- A regiszteradat frissítve
- 2026. június 18.
Ki vehet részt
The trial is looking for adults with diabetes who have nerve damage in the legs and feet (diabetic peripheral neuropathy). It tests shortwave heat therapy against a fake (sham) treatment.
- Életkor
- 18 to 85 years
- Nem
- All sexes
- A betegség stádiuma
- Nerve symptoms such as numbness, tingling, burning, cold or pain that started at or after the diabetes diagnosis. Signs on nerve tests may or may not be present. People must be able to complete the TCSS nerve assessment.
- Korábbi kezelés
- Nerve symptoms did not improve after adequate treatment with mecobalamin and other medicines.
- A részvétel fő kizáró okai
- Nerve damage from other causes, such as lower back spine problems, vitamin B12 deficiency, alcohol or Guillain-Barré syndrome
- Bleeding disorders or cancer
- Leg amputation below the knee, skin damage or infection at the treatment site, metal implants or a pacemaker
- Severe heart, liver or kidney problems (e.g., eGFR < 15 ml/min/1.73m²), or memory and thinking problems that prevent cooperation
- Pregnancy, breastfeeding or planning a pregnancy
A regiszter összes feltétele (15)A regiszter feltételeinek elrejtése
Ki vehet részt
- 1. Aged 18-85 years, regardless of gender, with the ability to act independently
- 2. Appearance of neuropathic symptoms or signs at the time of or after the diagnosis of diabetes, meeting the following criteria: presence of DPN symptoms (numbness, tingling, burning, cold, pain), with or without signs (abnormalities in any of ankle reflex, vibration sense, pinprick sensation, temperature sensation, or pressure sensation)
- 3. Able to complete the TCSS assessment
- 4. Understands the entire trial process, voluntarily participates in the study, and signs the informed consent form
- 5. Patients who did not respond to adequate treatment with mecobalamin and other medications
Ki nem vehet részt
- 1. Peripheral neuropathy caused by other reasons (such as lumbar spine lesions, vitamin B12 deficiency, uncontrolled hypothyroidism, alcohol intoxication, drug neurotoxicity, Guillain-Barré syndrome, etc.)
- 2. Hemorrhagic diseases, malignant tumors
- 3. History of below-knee amputation
- 4. Skin damage, infection at the treatment site, or presence of metal implants, pacemaker
- 8. Combined severe psychiatric disorders
- 9. Other conditions assessed by the investigator that prevent completion of the trial
- 5. Combined severe heart, liver, or kidney dysfunction (e.g., eGFR < 15 ml/min/1.73m²), or cognitive impairment preventing cooperation
- 6. Pregnancy, breastfeeding, or planning pregnancy
- 7. Participation in other interventional clinical trials within the past 3 months
- 10. Poor compliance
Alkalmassági kérdőív
Ez nem döntés: hogy ki vehet részt, azt csak a vizsgálat csapata mondhatja meg.
- Életkor
- Diabetic peripheral neuropathy
Ez a vizsgálat jelenleg itt érhető el: Kína.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study is a single-center, randomized, single-blind, sham-controlled clinical trial aimed at evaluating the efficacy and safety of shortwave therapy administered for five consecutive days in the treatment of diabetic peripheral neuropathy. The study plans to enroll 202 patients, who will be randomly assigned in a 1:1 ratio to either the shortwave therapy group (20 minutes daily for five consecutive days) or a sham treatment group with an identical appearance. The primary efficacy endpoint is the remission rate of the Toronto Clinical Scoring System score one month after treatment (a decrease of ≥1 point). Secondary endpoints include short-term efficacy, pain visual analog scale scores, quality of life scores, and safety indicators. The study hypothesizes that shortwave therapy can significantly improve neurological symptoms, with an expected remission rate of 65% in the treatment group and 20% in the control group, with the superiority margin set at 20%. This study will provide high-quality evidence-based medical evidence for the use of shortwave therapy in diabetic peripheral neuropathy.
A vizsgálat 2 csoportja
- Placebo treatment groupSzínlelt kezelés, összehasonlításként
Using devices that are completely identical in appearance, the treatment process, screen display, and sounds are the same as the active group, but the devices are specially modified and do not emit electromagnetic energy. To ensure the success of blinding, the skin temperature of the treatment area will be measured before and after treatment, but the specific values will not be disclosed to the subjects.
- Shortwave therapy groupA vizsgált kezelés
Using the CJ270-I model shortwave therapy instrument from Nanjing Congjing Biological Machinery Co., Ltd. Patients took a sitting position, placed both lower limbs into the therapy instrument, adjusted the power to 250W, frequency to 27.12MHz, once daily, 20 minutes each time, for 5 consecutive days.
Kezelés: Short-Wave Diathermy
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Shortwave Intervention for Diabetic Peripheral Neuropathy: A Randomized, Single-Blind, Sham-Controlled Trial(SIDPN)
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- Kérdések a feltételekről
- Forrás: NCT07625007: ki vehet részt
- A regiszteradat frissítve
- 2026. június 18.